Journal of Antimicrobial Chemotherapy, Vol 42, 807-810, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
FJ Schmitz, AC Fluit, M Luckefahr, B Engler, B Hofmann, J Verhoef, HP Heinz, U Hadding and ME Jones
In Staphylococcus aureus, in addition to mutations in the grl and gyr gene
loci, multidrug efflux pumps like NorA contribute to decreased
fluoroquinolone susceptibility. Efflux pumps can be inhibited by the plant
alkaloid reserpine, which, at 20 mg/L, reduced sparfloxacin, moxifloxacin
and ciprofloxacin IC50s and MICs by up to four-fold in 11, 21 and 48 of the
102 unrelated clinical isolates tested, respectively. The effect was less
pronounced with the hydrophobic drugs sparfloxacin and moxifloxacin than
with the hydrophilic drug ciprofloxacin and was stable in all 25 clonally
related isolates tested.
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus [In Process Citation]
Institute for Medical Microbiology and Virology, Heirich-Heine University Dusseldorf, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Chusri, I. Villanueva, S. P. Voravuthikunchai, and J. Davies Enhancing antibiotic activity: a strategy to control Acinetobacter infections J. Antimicrob. Chemother., December 1, 2009; 64(6): 1203 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Vecchione, B. Alexander Jr., and J. K. Sello Two Distinct Major Facilitator Superfamily Drug Efflux Pumps Mediate Chloramphenicol Resistance in Streptomyces coelicolor Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4673 - 4677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Robertson, E. J. Bonventre, T. B. Doyle, Q. Du, L. Duncan, T. W. Morris, E. D. Roche, D. Yan, and A. S. Lynch In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2313 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Robertson, E. J. Bonventre, T. B. Doyle, Q. Du, L. Duncan, T. W. Morris, E. D. Roche, D. Yan, and A. S. Lynch In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2324 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kumar, I. A. Khan, S. Koul, J. L. Koul, S. C. Taneja, I. Ali, F. Ali, S. Sharma, Z. M. Mirza, M. Kumar, et al. Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus J. Antimicrob. Chemother., June 1, 2008; 61(6): 1270 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Garvey and L. J. V. Piddock The Efflux Pump Inhibitor Reserpine Selects Multidrug-Resistant Streptococcus pneumoniae Strains That Overexpress the ABC Transporters PatA and PatB Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1677 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Stavri, L. J. V. Piddock, and S. Gibbons Bacterial efflux pump inhibitors from natural sources J. Antimicrob. Chemother., June 1, 2007; 59(6): 1247 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Marrer, K. Schad, A. T. Satoh, M. G. P. Page, M. M. Johnson, and L. J. V. Piddock Involvement of the Putative ATP-Dependent Efflux Proteins PatA and PatB in Fluoroquinolone Resistance of a Multidrug-Resistant Mutant of Streptococcus pneumoniae Antimicrob. Agents Chemother., February 1, 2006; 50(2): 685 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Jumbe, A. Louie, M. H. Miller, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, and G. L. Drusano Quinolone Efflux Pumps Play a Central Role in Emergence of Fluoroquinolone Resistance in Streptococcus pneumoniae Antimicrob. Agents Chemother., January 1, 2006; 50(1): 310 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Strahilevitz, Q. C. Truong-Bolduc, and D. C. Hooper DX-619, a Novel Des-Fluoro(6) Quinolone Manifesting Low Frequency of Selection of Resistant Staphylococcus aureus Mutants: Quinolone Resistance beyond Modification of Type II Topoisomerases Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5051 - 5057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Strahilevitz and D. C. Hooper Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1949 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Jacobs, S. Bajaksouzian, A. Windau, P. C. Appelbaum, M. V. Patel, S. V. Gupte, S. S. Bhagwat, N. J. De Souza, and H. F. Khorakiwala In Vitro Activity of the New Quinolone WCK 771 against Staphylococci Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3338 - 3342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lapierre, A. Huletsky, V. Fortin, F. J. Picard, P. H. Roy, M. Ouellette, and M. G. Bergeron Real-Time PCR Assay for Detection of Fluoroquinolone Resistance Associated with grlA Mutations in Staphylococcus aureus J. Clin. Microbiol., July 1, 2003; 41(7): 3246 - 3251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, M. Boos, S. Mayer, H. Jagusch, and A. C. Fluit Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother., February 1, 2002; 49(2): 283 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Entenza, Y. A. Que, J. Vouillamoz, M. P. Glauser, and P. Moreillon Efficacies of Moxifloxacin, Ciprofloxacin, and Vancomycin against Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus Expressing Various Degrees of Ciprofloxacin Resistance Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3076 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Linde, M. Schmidt, E. Fuchs, U. Reischl, H.-H. Niller, and N. Lehn In Vitro Activities of Six Quinolones and Mechanisms of Resistance in Staphylococcus aureus and Coagulase-Negative Staphylococci Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1553 - 1557. [Abstract] [Full Text]
|
|
|
|
|
|
K. Poole Efflux-Mediated Resistance to Fluoroquinolones in Gram-Positive Bacteria and the Mycobacteria Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2595 - 2599. [Full Text]
|
|
|
|
|
|
M. E. Jones, A. M. Staples, I. Critchley, C. Thornsberry, P. Heinze, H. D. Engler, and D. F. Sahm Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2645 - 2652. [Abstract] [Full Text]
|
|
|
|
|
|
F.-J. Schmitz, A. C. Fluit, D. Milatovic, J. Verhoef, H.-P. Heinz, and S. Brisse In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus J. Antimicrob. Chemother., July 1, 2000; 46(1): 109 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Jones, D. F. Sahm, N. Martin, S. Scheuring, P. Heisig, C. Thornsberry, K. Köhrer, and F.-J. Schmitz Prevalence of gyrA, gyrB, parC, and parE Mutations in Clinical Isolates of Streptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season Antimicrob. Agents Chemother., February 1, 2000; 44(2): 462 - 466. [Abstract] [Full Text]
|
|
|
|
|
|
P. N. Markham, E. Westhaus, K. Klyachko, M. E. Johnson, and A. A. Neyfakh Multiple Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2404 - 2408. [Abstract] [Full Text]
|
|